Thursday, 16 February 2017

Dr Reddy's gets unfavourable ruling in US over anti-nausea drug

Dr Reddy's Laboratories on Thursday said it received an unfavorable ruling in a US court regarding a patent infringement case over its anti-nausea injection Aloxi. The company said the US Court for the District of New Jersey had issued its opinion regarding Helsinn Healthcare's patent infringement claims against Dr Reddy's proposed palonosetron product. 

Dr Reddy's had filed an NDA (new drug application) for Aloxi about three year ago and Helsinn had challenged it. The court found that Dr Reddy's proposed drug -- palonosetron hydrochloride 0.25 mg/5 ml -- infringes on certain claims of US patents. The company added it is disappointed at the decision and intends to pursue an appeal in due course.

Intraday Calls back to back technical support and more just click here for you Stock market trading

No comments:

Post a Comment